Research programme: anti-FGF8 monoclonal antibody - BioWa

Drug Profile

Research programme: anti-FGF8 monoclonal antibody - BioWa

Alternative Names: BIW-7034; BW-8406

Latest Information Update: 01 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer BioWa
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Rheumatoid arthritis; Solid tumours

Highest Development Phases

  • Discontinued Osteoarthritis; Prostate cancer; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 23 Oct 2008 Preclinical development is ongoing in USA
  • 21 Oct 2005 Anti-FGF8 monoclonal antibody has been licensed to BioWa worldwide, except Asia
  • 18 Aug 2005 This programme is still in active development for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top